Through appetite suppression, delayed gastric emptying, and central nervous system effects on food reward pathways, these drugs cause significant weight loss
As part of the prior authorization process for Bridge, prescribing clinicians will need to attest that the GLP-1 prescription is for weight reduction and weight management and that beneficiaries meet the clinical criteria and do not have a diagnosis of type 2 diabetes, OSA, or MASH that would make them eligible for GLP-1 coverage under Part D
Always confirm your pen type first
Clinically approved options like Mounjaro and Wegovy are backed by extensive trials, regulated by the MHRA, and are proven to deliver real results
Meet Lemme Reset: Promote your body's GLP-1 production, reduce hunger and cravings and promote healthy weight management with 3 clinically-studied ingredients.* | Lemme
Users have experienced less hot flashes, more energy and improved moods